This review revealed a number of peer-reviewed papers focusing on bromfenac as an adjunct to anti-VEGF therapy in neovascular age-related macular degeneration, diabetic macular edema, and macular edema associated with retinal vein occlusion. This evidence concerns the gene VEGFA and macular retinal edema.